What is the Siliq REMS Program?
A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the FDA can require for medications with serious safety concerns, to ensure that the benefits of the medication outweigh its risks. The goal of the Siliq REMS Program is to manage the risk of suicidal ideation and behavior which occurred in some patients who were treated with Siliq during clinical trials.
What is Siliq?
Siliq (brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist used for the treatment of adults with moderate to severe plaque psoriasis. It is used in patients who may benefit from systemic therapy (such as an injection) or phototherapy (ultraviolet light treatment), and who have not responded or lost response to other systemic therapy.
Siliq is administered as a subcutaneous injection at Weeks 0, 1, and 2, and then every 2 weeks.
What is the risk associated with Siliq?
Because of the risk of suicidal ideation and behavior, the Siliq product label includes a Boxed Warning, and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.
- Doctors who prescribe Siliq should weigh potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior.
- Patients must sign a Patient-Prescriber Agreement Form and be made aware of the need to seek medical help right away should they experience new or worsening suicidal thoughts or behavior, feelings of depression, anxiety or other mood changes.
- Pharmacies must be certified with the program and must only dispense Siliq to patients who are authorized to receive it.
It is not known if Siliq causes suicidal thoughts or behavior, but the risk is higher in patients who have a history of suicidal thoughts or depression. Patients with new or worsening suicidal thoughts and behavior should get medical help right away if they notice any of the following symptoms:
- new or worsening depression or anxiety
- thoughts of suicide, dying, or hurting yourself
- changes in behavior or mood
- acting on dangerous impulses
- attempt to commit suicide
Patients who are prescribed Siliq will need to carry a Siliq Patient Wallet Card which lists which symptoms that require immediate medical help. The card must be carried at all times and needs to be shown to all healthcare providers.
Related questions
References
- U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies | REMS. Available at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems [Accessed April 8, 2021]
- U.S. Food and Drug Administration. Siliq Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf [Accessed April 8, 2021]
- SILIQ REMS Available at https://siliqrems.com/SiliqUI/home.u [Accessed April 8, 2021]
Read next
Where should you not use triamcinolone acetonide cream?
You should not use topical corticosteroids like triamcinolone acetonide cream on your face, groin, or axillae (underarm, armpit) unless directed by your doctor. Using triamcinolone in these areas may lead to unwanted side effects like acne, prominent blood vessels, skin thinning (atrophy), changes in skin color or unwanted hair growth. Continue reading
Halobetasol vs. clobetasol - How do they compare?
Halobetasol and clobetasol are both classified as super high-potency or high-potency topical corticosteroid (“steroid”) creams used on the skin. They are both FDA-approved to treat plaque psoriasis and skin conditions that are responsive to topical corticosteroids, such as dermatitis and eczema (atopic dermatitis). They lessen skin redness and pain, itching, dryness and scaling. Continue reading
Does taking vitamin D help with psoriasis?
Experts cannot say if oral vitamin D helps improve psoriasis symptoms, because overall, trial results have been mixed. While some open-label studies show a moderate to marked improvement (with some reports of remission), most double-blinded RCTs have shown only slight or no improvement. Supplementation could be considered on a case-by-case basis. Continue reading
Related medical questions
- What causes Plaque Psoriasis?
- Sotyktu vs Otezla: How do they compare?
- How long does it take for Otezla to work?
- How do you inject Humira?
- How to stop taking Otezla?
- Cosentyx vs Humira: How do they compare?
- What are 6 key Taltz side effects to watch out for?
- What's the dosing schedule for Skyrizi?
- How long does Cimzia take to work?
- What happens if Cosentyx is not refrigerated?
- How long does Cosentyx take to work?
- What is the mechanism of action of infliximab?
- Who is the actress in the Stelara commercial?
- Does Cosentyx cause weight gain or loss?
- Can Enstilar be used on the scalp?
- Who makes Otezla and why is it so expensive?
- Is Otezla (apremilast) an immunosuppressant?
- Does Skyrizi cause cancer?
- How long does it take for Sotyktu to work?
- Does Otezla cause weight gain?
- Can you drink alcohol while taking Skyrizi?
- How long does it take for Tremfya to work?
- What is the difference between Amjevita and Humira?
- Can Enbrel (etanercept) be taken with antibiotics?
- How and where do you inject Tremfya?
- How long can Tremfya be out of the fridge?
- How and where is the Cimzia injection given?
- Skyrizi vs Humira for plaque psoriasis - How do they compare?
- Can Tremfya cause cancer?
- How long can I take Sotyktu for?
Drug information
- Siliq Information for Consumers
- Siliq prescribing info & package insert (for Health Professionals)
- Side Effects of Siliq (detailed)
Related support groups
- Siliq (2 questions, 3 members)
- Plaque Psoriasis (86 questions, 69 members)